<DOC>
	<DOCNO>NCT00575913</DOCNO>
	<brief_summary>To assess , daily practice condition , safety profile efficacy new formulation alfuzosin administer daily ( Xatral XL ) patient low urinary tract symptom ( LUTS ) suggestive benign prostatic hyperplasia ( BPH ) .</brief_summary>
	<brief_title>Alfuzosin XL Lower Urinary Tract Symptoms Efficacy Sexuality Study</brief_title>
	<detailed_description />
	<mesh_term>Lower Urinary Tract Symptoms</mesh_term>
	<mesh_term>Prostatic Diseases</mesh_term>
	<mesh_term>Alfuzosin</mesh_term>
	<criteria>Ambulatory patient suffer low urinary tract symptom suggestive BPH . Patients require BPH surgery immediately within 12 follow month : Acute renal obstruction Chronic renal obstruction Chronic renal failure BPH Bladder stone Recurrent urinary tract infection Other bladder pathology cancer bladder , bladder bidiverticulum ( big size ) Hematuria BPH Patients whose urinary symptom satisfactorily control BPH medication ( alphablockers 5 alphareductase ) Patients previously improve alpha1blocker treatment Known hypersensitivity alfuzosin History postural hypotension syncope Combination alpha1blockers Hepatic enzyme ( SGOT or/and SGPT ) &gt; 1.5 Upper Normal Limit Unstable angina pectoris Severe concomitant condition threaten life . Patients fail treatment finasteride ( Proscar ) Patients neuropathic bladder . Patients history previous surgery BPH Patients high risk prostate cancer base clinical judgement investigator The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>